Erubin 10

• Cancer: Indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Used for lymphoma, multiple myeloma, solid tumors, acute leukemias.

Adult Dose:

• Adjuvant Breast Cancer (FEC-100): 5-Fluorouracil 500 mg/m² + Epirubicin 100 mg/m² + Cyclophosphamide 500 mg/m² IV Day 1, q21Days x 6 cycles.
• CEF-120: Cyclophosphamide 75 mg/m² PO D 1-14 + Epirubicin 60 mg/m² IV D 1,8 + 5-Fluorouracil 500 mg/m² IV D 1,8; q28Days x 6 cycles.
• Single Agent: 60-90 mg/m² every 3-4 weeks; Max total cumulative dose: 0.9-1 g/m².
• Palliative Care: 12.5-25 mg/m² once weekly.

Hepatic Impairment: Bilirubin 3 mg/dL or AST > 4 x ULN: 25% of recommended starting dose; Severe hepatic impairment: Not recommended.

Renal Dose: SCr >5 mg/dL: Decrease dose by 50%; test cardiac ejection fraction via MUGA before starting treatment.

Common Side Effects:

• Myelosuppression
• Cardiotoxicity
• Alopecia (hair loss)
• Hyperpyrexia
• Lethargy
• Amenorrhea (menstrual cessation)
• Nausea
• Vomiting
• Diarrhea
• Fever
• Rash
• Anorexia
• Reddish appearance of urine (1-2 days)

Precautions:

• Epirubicin Hydrochloride may cause side effects which could affect your ability to drive.
• It may make you feel tired or sleepy. Do not drive or do anything requiring mental focus until you know how it affects you.
• Use a reliable contraceptive method during treatment and for 6 months after stopping treatment.
• Your doctor may get regular blood tests done to monitor your blood cells, liver, and heart function during treatment.
• Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
• Procedures for proper handling and disposal of anticancer drugs should be used when handling and preparing Epirubicin.
• Should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy.